Navigation Links
Vertex Plans to Provide Access to Potential CF Therapy VX-770 for Patients with Critical Medical Need
Date:6/10/2011

BETHESDA, Md., June 10, 2011 /PRNewswire-USNewswire/ -- Vertex Pharmaceuticals Inc. announced a plan to provide VX-770, a CF medicine in development, to people with the G551D mutation who are in critical medical need and may benefit from treatment prior to potential approval of the drug from the U.S. Food and Drug Administration (FDA).

Pending FDA review and approval, Vertex expects to open the program at clinical sites in the United States as early as July.

"We are delighted that Vertex is making VX-770 available to patients through an expanded access program," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "This underscores Vertex's commitment to do what is right for the CF community."

The company is on track to submit a New Drug Application for VX-770 to the FDA in the second half of 2011.

VX-770 is an oral drug in development that targets the underlying cause of cystic fibrosis.

Results from Phase 3 clinical trials released this year showed that those who took the drug had marked improvements in lung function and other key indicators of the disease, including sweat chloride levels, likelihood of pulmonary exacerbations and body weight.

The CF Foundation worked with Vertex to discover VX-770, and has provided substantial scientific, financial and clinical support throughout the development process.

The Vertex VX-770 drug access program is for people with highly limited lung function and who meet other criteria. For information on eligibility or other details, call Vertex Medical Information at 1-877-634-VRTX (8789).

About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supp
'/>"/>

SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
2. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting
5. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
6. KemPharm, Inc. Announces Plans to Launch KP106 as First Oral Film Dosage Form for ADHD
7. Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans
8. China Botanic Pharmaceutical Announces Plans to Switch to Renewable Bio-Fuel - Straw Pellets
9. Generex Plans Rights Offering Upon Approval of Reverse Stock Split and Listing on a National Stock Exchange
10. Qmed Announces Increase in Dedicated Staff as Part of Development Plans for 2011
11. Plans to Overhaul Ambulance Industry Met With Enthusiasm: Online Marketplace for Emergency Medical Services Introduces Largest Selection of Products and Services on the Web
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Alternatives to Needle-Based Systems for Vaccine ... http://www.reportlinker.com/p0590267/Needle-Free-Drug-Delivery-The-Market-for-Alternatives-to-Needle-Based-Systems-for-Vaccine-and-Biologics.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology The line ...
... WOONSOCKET, R.I., Aug. 16, 2011 Medicare Part D ... to pay 100 percent of previously subsidized prescription costs, ... they are to switch to more affordable or generic ... Medicine concludes. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ...
Cached Medicine Technology:Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics 2Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics 3Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics 4Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics 5CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3
(Date:7/10/2014)... The benefits of medical imaging far outweigh the ... Right Way, with The Right Radiation Dose. However, overuse ... Mayo Clinic is leading a collaborative effort to ensure ... published online in the Journal of Patient Safety ... Joint Commission, the Intersociety Accreditation Commission, and the Centers ...
(Date:7/10/2014)... For decades, health-conscious people around the globe have ... figuring this was one of the paths to good ... clinical trials of antioxidant supplements have repeatedly dashed the ... their cancer risk. Virtually all such trials have ... In fact, in several trials antioxidant supplementation has been ...
(Date:7/10/2014)... Men who experience hot flashes are unlikely to ... from their silent suffering if they are willing ... a Baylor University case study., After seven weeks of ... hot flashes following prostate cancer surgery showed a drastic ... impressive improvement in sleep quality, according to the study., ...
(Date:7/9/2014)... MA -- Vasectomy was associated with a small increased ... advanced or lethal prostate cancer according to a new ... researchers found that the association remained even among men ... of lethal cancer cannot be explained by diagnostic bias. ... date to look at the link between vasectomy and ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Lung cancer study hints at new treatments 2
... CHICAGO, June 24 Bally Total Fitness Holding,Corporation today ... its Chief Executive Officer, effective July 1. Mr. Sheehan ... Directors., Mr. Sheehan, age 46, served as the ... serving as Chief Operating Officer, Mr. Sheehan,served as Executive ...
... control symptoms better, studies show , , TUESDAY, June 24 ... delivery system for an older drug appear to hold ... In the first study, patients taking the drug SLV308 ... tremors and slowness of movement. The results also indicate ...
... announced today Reproductive Health Matters , May 2008 ... Promoting Sexual and Reproductive rights". Under conditions of global ... growing numbers of refugees and internally displaced persons (IDPs) ... right to have rights,. By the end of ...
... Devices known as brain-machine interfaces could someday be ... prosthetic limbs with just their thoughts. Now, University of ... devising a way for computerized devices not only to ... with the brain as it learns. , Instead of ...
... but doing little to ... within the facility, CHICAGO, June 24 The American ... survey asking 1,000 women,their opinions on medical spas. Findings revealed ... customers of these facilities.,Yet half of those women are compromising ...
... The Rehabilitation Institute,of Chicago and MediCom Worldwide, Inc. ... July 18th and 19th. The meeting will be ... University in Chicago., This year, the conference ... scientific agenda will focus on the latest information,issues, ...
Cached Medicine News:Health News:Bally Total Fitness Announces New Chief Executive Officer 2Health News:New Hope for Parkinson's Patients 2Health News:May 2008 issue on conflict and crisis settings: Promoting sexual and reproductive rights 2Health News:Researchers develop neural implant that learns with the brain 2Health News:Researchers develop neural implant that learns with the brain 3Health News:Millennials' Medspa Influence 2Health News:3rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide, Inc. 2
Ethicon, medium clip size, 10mm, rotatable take apart...
Solid phase capture sandwich ELISA assay using a microwell format....
The C-Reactive Protein (CRP) assay is used for the quantitative analysis of C-reactive protein in human serum and plasma. Kit is for use with the Abbot Laboratories Aeroset, ARCHITECT c8000 or ARCHI...
... broad menu clinical chemistry analyzer designed for ... Care givers can now perform routine multi-chemistry ... minute of hands-on time. Complete panel results ... expensive laboratory analyzers are available in under ...
Medicine Products: